Departamentos

  1. Portada
  2. Investigación
  3. [...]
  4. Participación directa en reuniones científicas
  5. Reuniones científicas internacionales

Reuniones científicas internacionales

PONENTE: Dr. Juan Tamargo.  12th Course of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. "New versus old designs in clinical trials”.Moderador. Programme all about Clinical Trials. Estocolmo, 12 de diciembre de 2019.

PONENTE: Dr. Juan Tamargo.   Training Course of the ESC Working Group on Cardiovascular Pharmacotherapy. "Drugs metabolism in the elderly”.
Ponencia. "Programme all about Clinical Trials". Chairman: Sesion 2 "Diuretics". Londres, 25 de octubre de 2019.

PONENTE: Dr. Juan Tamargo. 5th The New Heart Rhythm Update. "New therapeutic approaches in the treatment of type 2 diabtes mellitus"
Moderador. Session 5: "The new rhythm in heart failure and hypertension management". Bucarest, 18-19 de octubre de 2019

PONENTE: Dr. Juan Tamargo.  "¿Son todos los ACODs iguales?".  Symposium: Diferentes perfiles de pacientes, diferentes anticoagulantes. Barcelona, 17-19 de octubre de 2019

SESIÓN MAGISTRAL: Dr. Juan Tamargo. XXIII Jornadas de avances terapéuticos en enfermedades cardiovacsulares y en insuficiencia cardiaca. "Últimos avances terapéuticos en enfermedades cardiovacsulares". Ibiza, 4 de octubre de 2019PONENTE: Dr. Juan Tamargo. IberiCardio. I Jornadas del estudio IBERCAN. "El tratamiento anticoagulante desde el punto de vista farmacológico". Sesión: Anticoagulantes orales: manejo y controversias en la práctica clínica. Madrid, 13 de septiembre de 2019

PONENTE. EuroCVP Congress - Cardiovascular Pharmacotherpay 2019. Cardiovascular Pharmacotherapy at old age. "Age-specific alterations in drug maetabolims". Viena, Austria  17-18 de mayo de 2019.

PONENTE. 15th Annual Congress of the European Cardiac Arrhythmia Society. Do we nedd antiarrhythmic durg therapy in the AF ablation era? "Use of antiarrhythmic therapy before and after electrical cardioversio2. ECAS 2019. 15th Annual Congress of the European Cardiac Arrhythmia Society. Marsella, 16-18 de junio de 2019.

CHAIRMAN. Horizonts in discovery: Using gnetics to identify new drug targets. European Society of Cardiology Congress and World Congress of cardiology. Paris, 31 de agosto de 2019.

PONENTE. SymposiumPrinciples for a smooth cardiovascular drugs therapy in the elderly. "Pharmacological issues related to ageing". European Society of Cardiology Congress and World Congress of cardiology. Paris, 31 de agosto de 2019.

PONENTE. 13th International Meeting. Arial fibrillation and heart failure: The ugly and the nasty. "Is the AAD efficay concept changing in AF patients?. Bolonia (Italia). 14-15 de febrero de 2019.

ESC (European Society of Cardiology) Congress 2018. , 25-29 de agosto de 2018. J. Moderador. Expert Session: "Safety first: avoiding adverse events with new cardiovacular drugs". Ponente "Safey first: avoiding adverse events with new cardiovascular drugas - Take Home Message". Congreso: ESC (European Society of Cardiology) Congress. Munich, 25-29 de agosto de 2018.

Tamargo J. Ponente "Are regulations for generic CV drugs". Symnposium: "Are generic drugs safe in heart failure?". Congreso: ESC (European Society of Cardiology) Congress. Munich, 25-29 de agosto de 2018.

Tamargo J. Moderador. Case-based Session "Antithrombotics and cancer: challenges in clinical practice?" Congreso: ESC (European Society of Cardiology) Congress. Munich, 25-29 de agosto de 2018.

38th Meeting Spanish Society of Pharmacology y 9th Spanish Meeting of Pharmacogenetics and Pharmacogenomics. Santiago de Compostela, 18-22 de junio de 2018. PONENTE. Roundtable: Pharmacology of cardiometabolic diseases. "New therapeutic approaches in the treatment of type 2 diabetes mellitus". 38th Meeting Spanish Society of Pharmacology y 9th Spanish Meeting of Pharmacogenetics and Pharmacogenomics. Santiago de Compostela, 20 de junio, 2018. Prof. Juan Tamargo

30 Congreso Nacional de la Sociedad Española de Medicina de Urgencias y Emergencias. Toledo, 7 de junio de 2018
CONFERENCIA MAGISTRAL “El futuro de las arritmias en la fase aguda”. Los fármacos antiarrítmicos: una historia llena de futuro. Prof. Juan Tamargo

The 6th Annual Congress of the ESC WG on Cardiovascular Pharmacotherapy. EuroCVP 2018. Tel Aviv, Israel, 13-14 de mayo de 2018.
PONENTE. "The 2018 update on blood cholesteroal treatment in coronary patients". "Drugs and treatment". European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Prof. Juan Tamargo. PONENTE. "Clinical Trials Programme all About Clinical Trials". "Traditional versus novel trial designing". European Society of Cardiology Working Group on Cardiovascular. Prof. Juan Tamargo

6ª Jornadas Nacionales Nefrourológicoas SEMERGEN. Segovia, 13 de abril de 2018. PONENTE. Mesa Redonda: Avances en vejiga hiperactiva. Nuevos fármacos. "Perfíl farmacológico de la propiverina". Prof. Juan Tamargo

11th course of the ESC Working Group of Cardiovascular Pharmacotherapy "All about clinical trials". Bruselas, 2 de marzo de 2018
PONENTE. "Traditional versus novel trial designing". Prof. Juan Tamargo

ESC Congress. European Society of Cardiology. Londres, 29 de agosto al 2 de septiembre de 2015. Sesión. Mechanisms of action of emerging therapeutics. Signalling "PARADIGM" for treating heart failure.. Ponente: Dr. Juan Tamargo.

Controversies in the treatment of Atrial Fibrillation and Hypertension Chairperson: Dr. Juan Tamargo Menéndez     

The 12th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT). One vibrant community of clinical pharmacologists. Madrid, 27-30 de junio de 2015. Track 3 (Clinical practice). Heterogeneity in drug response: Pharmacological determinants and their regulatory and clinical implications, “Understanding the pharmacological factors that influence heterogeneity in drug response". Ponente: Dr. Juan Tamargo.            

Europace. EHRA 2015. Cardiostim. Milan, Italia, 21-24 de juio de 2015. Sesión. Emerging molecular strategies in antiarrhythmic therapy. “Is there a therapeutic role for microRNAs in heart rhythm disorders?” Ponente: Dr. Ricardo Caballero   

Eurocvp 2015 Congress. Roma, 29-31 de mayo de 2015. Gender differences in cardiovascular pharmacology. Moderador: Dr. Juan Tamargo. "Can we generalise to both gender the results of cardiovascular clinical trials?". Ponente: Dr. Juan Tamargo. Pharmacotherapy of Heart Failure - Joint sessions with the Heart Failure Association, "What is on the horizon for the pharmacological treatment of patients with chronic heart failure after PARADIGM-HF". Ponente: Dr. Juan Tamargo Menéndez. Panel discussion: NOAC antidotes. Moderador: Dr. Juan Tamargo 

11th Annual Congress of the European CArdiac Arrhythmia Society. Paris, 19-21 de abril de 2015. Session SP-06. Atrial Fibrillation: Beyond Stroke Prevention, "Role of Pharmacology". Ponente: Dr. Juan Tamargo.

11º International Meeting Atrial Fibrillation 2015. Sociedad Española de Cardiología, Atrial Fibrillation and heart failure: the ugly and the nasty. Bologna, Italia, 19-20 de febrero de 2015. Sesión. Drugs and AF, “Old AAD are still effective and safe”. Ponente: Dr. Juan Tamargo.    

Cardiodays. University of Ferrara. Ferrara, Italia, 24-25 de octubre de 2014. Scientific Session. Ponencia: Insight into new pharmacological approaches to atrial fibrillation. Ponente: Dr. Juan Tamargo. Debate: C. Blomstrom-Lundqvist, D Dobrev, R Ferrari, P Kirchhof, C. Pappone, U Ravens, J Tamargo, L. Tavazzi, GG Vicedomini.

Cardiovascular management in your angina patients with Type 2 diabetes: a critical unmet need (EASD 2014). Symposium on the occasion of the 50th Annual Meeting of the European Association for the Study of Diabetes. Viena, 15 de septiembre de 2014. Ponencia: The late sodium current inhibition: effective approach in a large ptients population. Ponente: Dr. Juan Tamargo.      

ESC Congress 2014. European Society of Cardiology. Barcelona, 30 de agosto - 3 de septiembre de 2014. Sesión: Atrial fibrillation: an old problema with new solutions? Ponencia: The novel oral anticoagulants: how best to use them?. Ponente: Dr. Juan Tamargo.

Cardiostim 2014. EHRA Europace. Niza, 18-21 junio de 2014. Session 127. Atrial Fibrillation III. "Dosing Guidelines of NOACS in the elderly, renal insufficiency, drug-drug interactions”. Ponente: Dr. Juan Tamargo.       

1er. Simposio en Investigación Biomédica. "Advances and perspectives in Cardiovascular Biomedicine". Madrid, 21 de marzo de 2014. Moderador de la Sesión Plenaria: Dr. Juan Tamargo.

Round table on new SCAD ESC Guidelines. París, 27-28 de febrero de 2014. Participants: AJ. Camm (UK), J. López-Sendón (Sp), G. Ambrosio (It), J. Tamargo (Sp), A. Mugelli (It), M. Komajda (Fr).

10th Global CardioVascular Clinical Trialists Forum. Paris, 6-7 de diciembre de 2013. Thrombosis trialists worksho: Competing new therapies in atrial fibrillation and heart failure. “Coronary arterial disease trials: Change in practice and change in pathophysiological understanding”. Lessons from first post FDA guidance case studies of diabetes cv outcomes trials. Ponente: Juan Tamargo.

XVII Jornadas de avances terapéuticos en enfermedades cardiovasculares y en I.C. Ibiza, 26-28 de septiembre de 2013. Sesión Magistral: Últimos avances terapéuticos en I.C. Dr. Juan Tamargo.


Publicaciones anteriores:

 

  1. PONENTE en el Meeting ‘Definition, Causes and Therapeutic Options in Acute Heart Failure’. “Inotropic drugs in acute heart failure”. Zurich (Suiza), Febrero 2004
  2. CHAIRPERSON en la sesión ‘Myocardial disease: from the bench’, celebrada en el Madrid Arryhthmia and Myocardium 2004 Meeting. Madrid, Febrero 2004
  3. PONENTE en la ‘Gordon Moe Memorial Lecture’, celebrada en el Madrid Arryhthmia and Myocardium 2004 Meeting. “ARB and ACEI to counter-remodel the atria in patients with atrial fibrillation”. Madrid, Febrero 2004
  4. PONENTE en el 1er. Encuentro Internacional de Medicina Cardiovascular: El síndrome metabólico como objetivo de futuro: “Advances in the treatment of heart failure”. Marbella (Málaga), Mayo 2004.
  5. CHAIRMAN en la 24th European Section Meeting (Cardiovascular Pharmacology) of the International Society for Heart Research (ISHR). Dresden (Alemania), Junio 2004.
  6. CHAIRMAN en la Sesión ‘Structure and Function of Cardiac Ion Channels’ en el European Society of Cardiology Congress 2004. Munich (Alemania), Septiembre 2004.
  7. CHAIRMAN en la Sesión ‘Conduction of the Electrial Impulse’ en el European Society of Cardiology Congress 2004. Munich (Alemania), Septiembre 2004.
  8. PONENTE en el XXVIII Meeting of the European Working Group on Cardiac Cellular Electrophysiology. “Effects of the inhibitors of the angiotensin-aldosterone system on cardiac potassum currents. Szeged (Hungría), Septiembre 2004.
  9. PONENTE en la Plenary Session ‘Antiarrhythmic Therapy Drugs Devices and Ablation’, celebrada en el 27th World Congress of Internal Medicine. “Antiarrhythmic drug therapy: past, present and future”. Granada, Septiembre-Octubre 2004. 
  10. CHAIRMAN en la Session 4 ‘Inotropes in acute heart failure. Beta-blockers and inotropes in AHF’, en la Reunión ‘Acute Heart Failure: an Emerging Problem in Developed Societies. The Management of Acute Heart Failure in the Era of Beta-blockade Therapy’. European Society of Cardiology. Porto (Portugal), Octubre 2004.
  11. PONENTE en la Session 2 ‘Monitoring, hemodynamic stabilization, diagnostic procedures, nonpharmacological therapy’, en el Symposium ‘Acute Heart Failure: an Emerging Problem in Developed Societies. The Management of Acute Heart Failure in the Era of Beta-blockade Therapy’. “Clinical and hemodynamic stabilization – The pharmacological spctrum (Diuretics, Vasodilators, Inotropes with vasodilating properties, Vasopressors with inotropic properties, Vasopressors)”. European Society of Cardiology. Porto (Portugal), Octubre 2004.
  12. PONENTE en ‘Frontiers in Cardiovascular Research’ “Modulation of potassium channels by angiotensin II and aldosterone. Revisiting the myocardial effects of the pharmacological blockade of the RAAS”. Pamplona, Octubre 2004.
  13. PONENTE en el International Satellite Symposium ‘Mechanism and Treatment of Lethal Arrhythmias’, celebrado en el 21st Annual Meeting of the Japanese Section of the International Society for Heart Research (ISHR). “Drug-induced long QT”. Kofu (Japón), Noviembre 2004.
  14. PONENTE en una Invited Lecture en el 21st Annual Meeting of the Japanese Section of the International Society for Heart Research (ISHR). “Pharmacological control of atrial fibrillation”. Kofu (Japón), Noviembre 2004.
  15. DIRECTOR del Madrid Arrhythmia and Myocardium Meeting 2005 (Atrial Fibrillation, Sudden Death, and Heart Failure). Madrid, Febrero 2005.
  16. CHAIRPERSON en ‘Improving the Treatment of Heart Failure after Myocardial Infarction’, celebrado en el Madrid Arrhythmia and Myocardium Meeting 2005 (Atrial Fibrillation, Sudden Death, and Heart Failure). Madrid, Febrero 2005.
  17. PONENTE en el Abbott Levosimendan Synmposium. “Levosimendan, an inotropic, vasodilating drug”. Madrid Arrhythmia and Myocardium Meeting 2005 (Atrial Fibrillation, Sudden Death, and Heart Failure). Madrid, Febrero 2005.
  18. PONENTE en el Dirk Durre Memorial Symposium. “Electrical and mechanical consequences of cardiac potassium channels block”. Madrid Arrhythmia and Myocardium Meeting 2005 (Atrial Fibrillation, Sudden Death, and Heart Failure). Madrid, Febrero 2005.
  19. MODERADOR de la Sesión ‘Cardiovascular Research at the Charité’ en el Joint Charité/SEH-LELHA Meeting (Evolving Role of Angiotensin Receptor Blockade in the Progression of Cardiovascular Disease). Berlín (Alemania), Abril 2005.
  20. PONENTE en la 2ª Conferencia Internacional Mediterránea sobre Riesgo Cardiovascular. “New tendencies in the treatment of arterial hypertension”. Murcia, Abril 2005.
  21. SEMINARIO impartido en el Masonic Medical Research Laboratory (Utica, N.Y., USA), “Effect of nitric oxide on hKv1.5 channels”. Septiembre 2005.
  22. PONENTE en el Anlo-Spanish Cardiovascular Disease Forum. “Combination therapy for patients with cardiovascular risk”. Londres (Gran Bretaña), Noviembre 2005.
  23. PONENTE, en el Annual Meeting of the Portuguese Association of Arrhythmology, Pacing and Electrophysiology, “Antiarrhythmic drugs – perspectives for the future”. Cascaias (Portugal), 21 Enero 2006.
  24. PONENTE en la Mesa Redonda ‘Intervención sobre los Factores de Progresión del Daño Vascular y Renal’. “Prevención del daño vascular y renal: ¿ ACE inhibitors, ARB or both ?”, celebrada en la V Conferencia Internacional ‘Hipertensión y Riñón’. Hipertensión y Riesgo Vascular Asociado a la Enfermedad Renal. Madrid, 16/18 Febrero 2006.
  25. PONENTE en el Astra-Zeneca Satellite Symposium ‘Candesartan: evidence beyond hypertension and current role in heart failure’. “Candesartan in atrial fibrillation: prevention of remodeling, direct action, or both?. Madrid Arrhythmia and Myocardium Meeting 2006. Madrid, 1/3 Marzo 2006.
  26. PONENTE en el Worshop on Heart Failure Controversies. “The pharmacology of beta-blockers ued in heart failure justifies potential therapeutic differences”. Madrid Arrhythmia and Myocardium Meeting 2006. Madrid, 1/3 Marzo 2006.
  27. CHAIRMAN en el Carlos Jiménez Díaz Memorial Symposium and Lecture. Madrid Arrhythmia and Myocardium Meeting 2006. Madrid, 1/3 Marzo 2006.
  28. PONENTE en el Barcelona AF Symposium. ‘New guideliness and recommendations for AF’. “Pharmacological treatment: Antiarrhythmic drugs”. Barcelona, 24/26 Marzo 2006.
  29. PONENTE en el 72 Annual Meeting of the German Society of Cardiology. “Long QT syndrome”. Mannheim (Alemania), 20/22 Abril 2006.
  30. CHAIRMAN del Topical Workshop ‘PPARgamma activation. New strategies in cardiovascular risk managemt’. 16th European Meeting on Hypertension. Madrid, 12/15 Junio 2006.
  31. PONENTE en el World Congress of Cardiology 2006 3M Satellite Symposium. “Assessing the acute and long-term safety of anti-arrhythmic drugs: pharmacological and clinical considerations”. Barcelona, 1 Septiembre 2006
  32. CHAIRMAN en la Mesa Redonda ‘What is New in Cardiovascular Drug Therapy’. Symposium International Society of Cardiovascular Pharmacotherapy. Barcelona, 1 Septiembre 2006.
  33. PONENTE en el Satellite Symposium ‘Early Treatment of Atrial Fibrillation: An Interactive Session – Contrasting Scenarios, Decisions and Treatment Choices’. “Assessing the acute and long-term risk/benefits of anti-arrhythmic drugs: pharmacological and clinical considerations”. World Congress of Cardiology 2006. Barcelona 2/6 Septiembre 2006.
  34. PONENTE en el Symposium ‘Acquired Abnormalities of Repolarisation. A Global problem’.  “Molecular mechanisms of drug-induced QT prolongation”. World Congress of Cardiology 2006. Barcelona 2/6 Septiembre 2006.
  35. PONENTE en la 3ª Conferencia Internacional Mediterránea sobre Riesgo Cardiovascular. “New drugs and strategies for the control of cardiovascular risk factors”. Murcia, 27/28 Abril 2007.
  36. CHAIRMAN en el Symposium ‘Remodeling, the heart returns to childhood’. XIX World Congress of the ISHR. Bolonia, 22/25 Junio 2007.
  37. MODERADOR de la sesión ‘Vascular Biology’. XIX World Congress of the International Society of Cardiovascular Pharmacology. Bolonia, 22/25 Junio 2007.
  38. PONENTE en el 14th International Congress of the International Society of Cardiovascular Pharmacology. “Emerging therapies for the management of decompensated heart failure”. Antalia (Turquía) 2007.
  39. PONENTE en el 14th International Congress of the International Society of Cardiovascular Pharmacology. “Atrial fibrillation asssociated with drug therapy”. Antalia (Turquía) 2007.
  40. PONENTE en la VI Conferencia Internacional ‘Hipertensión y Riñón’. Hipertensión y Riesgo Vascular asociado a la Enfermedad Renal. “New strategies to inhibit the renin-angiotensin-aldosterone system: direct renin inhibitors”. Madrid, 28/29 Febrero 2008.
  41. CONFERENCIA MAGISTRAL en el VIII Foro Iberoamericano de Cardiología. ‘Papel actual de los betabloqueantes en cardiología’. Huelva, 6/8 Marzo 2008.
  42. PONENTE en la sesión ‘Scientific Priorities 2008: horizontal areas’. II Innovative Medicines Iniciative (IMI) Information Day. “Farmacovigilance”. Fondo de Invstigaciones Sanitarias. Madrid 11 Marzo 2008.
  43. PONENTE en el ‘Symposium on Atrial Fibrillation and electrophysiological mechanisms involved in its genesis and treatment’. “Block of Kv1.5. Useful drugs in the treatment of the atrial fibrillation”. 32nd Meeting of the European Working Group on Cardiac Cellular Electrophysiology. Madrid, 18/20 de septiembre 2008.
  44. PONENTE en la sesión ‘Arrhythmias and antiarrhythmics’. “Effects of NO on human potassium channels”. 32nd Meeting of the European Working Group on Cardiac Cellular Electrophysiology. Madrid, 18/20 de septiembre 2008.
  45. PONENTE en el Cycle of Magistral Conferences in Cardiovascular Medicine. “Channelopathies from genetic to funcionality”. Hospital Clínico San Carlos. Madrid, 14-16 Octubre 2008.
  46. PONENTE en el VIII International Meeting on Atrial Fibrillation and heart failure: the ugly and the nasty. “Pharmacological treatment of atrial fibrillation”. Bologna (Italia), 26-27 de febrero, 2009.
  47. PONENTE, en el Meeting of the AF exchange Group. Paris, 19 de abril 2009.
  48. PONENTE en el Heart Rate Update Meeting “New electrophysiological targets for the pharamacological rhythm control in atrial fibrillation. Bucarest 24-25 de abril 2009.
  49. CHAIRMAN en la sesión “Arrhythmia: heart failure and ischemic heart disease”. Heart Rate Update Meeting, Bucarest 24-25 de abril 2009.
  50. PONENTE “The late sodium channel current: how valid as a new therapeutic target in angina?”. International Meeting de la European Society of Hypertension, Londres 25-26 de junio de 2009.
  51. PONENTE. “New investigational drugs for the management of acute heart failure syndromes”, 9th Congress of the European Association for Clinical Pharmacology and Therapeutics. Edinburgo, Julio 12-15, 2009.
  52. PONENTE “Pharmacological cardioversion – what constitutes cardioversion (and recurrence)?”, Workshop on regulatory aspects of atrial fibrillation. European Society of Cardiology-ESC Cardiovascular Round Table, Londres 15-156 de Septiembre de 2009.
  53. PONENTE “Is the underlying aetiology of atrial Fib/Fluter important?”, Workshop on regulatory aspects of atrial fibrillation. European Society of Cardiology-ESC Cardiovascular Round Table, Londres 15-156 de Septiembre de 2009.
  54. CHAIRMAN of the Session on “Channel pharmacology”. 33rd Meeting of the European Working Group on Cardiac Cellular Electrophysiology. Colonia (Alemania), Septiembre 2009.
  55. PONENTE, II Internqational symposium on cardiovascular health. “New genes associated with sudden cardiac death”. Fundación BBVA. Madrid, 1 de diciembre de 2009.
  56. CONFERENCIA en la VII Conferencia Internacional Hipertensión y Riñón. “Oral hypoglycemic agents in patients with chronic kidney disease”. Madrid 26 de febrero de 2010.
  57. PONENTE en el Symposium Diagnosis and treatment o chronic stable angina: new oppoortunities. “Ion sodium channels: a new target for ischemia?. ACC 59th Annual Scientific Session. Atlanta (USA), 13 de marzo de 2010.
  58. PONENTE en el Symposium on Chronic stable angina. “Pharmacological aspects of Ranolazine”. XXXI Congreso Nacional de la Sociedade Portuguesa de Cardiologia. Lisboa, 10 de abril de 2010.
  59. PONENTE en el 2nd International Meeting on Angina. Symposium Ischemia begets ischemia. “Late INa: the crucial time of the ischemia cascade”. Atenas 15-16 de abril 2010
  60. PONENTE en el Symposium Living on top with drug safety. “QT syndrome”. Barcelona,19 de mayo de 2010.
  61. PONENTE en el XVI World Congress of Pharmacology (IUPHAR). “New strategies in the treatment of heart failure”. Copenhaguen 22 de julio de 2010.
  62. PONENTE en el Symposium “Chronic stable angina, the tip of the iceberg: walk with a new innovative drug”. “Late sodium current: the crucial time of the ischemic cascade”. European Congress of Cardiology. Estocolmo 30 de Agosto 2010.
  63. PONENTE en el Meeting New approaches to cardiovascular diseases: from ion channels to bedside. “MOA of old and new antianginal drugs”. Erice (Italia), 4-5 de Novienbre 2010.
  64. INVITED member of the Committee for the new guideliness of the Lambeth Convention on cardiac arrhyhmias. Londres 6-7 de septiembre de 2010.
  65. PONENTE. Workshop on prevention of arterial thromboembolic events in atrial fibrillation. Committee for European Relations. European Society of Cardiology. Paris 28 de septiembre de 2010.
  66. PONENTE, Stepping into the world of angina pectoris management. “Late INa: the crucial time of the ischemic cascade”. 5th Baltic Atherosclerrotic Congress. Vilnius (lituania), 14-16 de octubre de 2010.
  67. PONENTE, New Approaches to cardiovascular diseases: from ion channels to bedside. “MOA of ald and new antiaginal drugs”. Ettore Majorana Foundation. Erice (Italia). 4-6 noviembre 2010.
  68. CHAIRMAN, 3er International Sympsium on Cardiovascular Health. “New Frontiers of Cardiovascular Research”. Fundación BBVA. Madrid, 1-2 de noviembre, 2010.
  69. PONENTE, EHRA Translational Science Course: Focus on Atrial Fibrillation. Atrial fibrillation: unmet needs and newly emerging drugs. “Atrial-selective Antiarrhythmic agents: dream of realty?”. Francia, 12 de febrero de 2011.
  70. PONENTE, IX International Meeting. Atrial fibrillation and heart failure: the ugly and the nasty. Session: Antyarrhythmic Drugs: what’s new and what’s effective. “An appraisal for old drugs”. Bolonia, 25 de febrero de 2011.
  71. PONENTE, XII International Forum for the Evaluation of Cardiovascular Care. Session 5: The hypertensive patient: an ischemic patient. “A haemodynamically independent agent for a new approach to coronary heart disease”. Budapest, 25 de marzo de 2011.
  72. PONENTE en el International Ion Channel Workshop. “Mechanisms of Inhibition”. R&D Centre. Almirall Ltd. Barcelona. June 2nd 2011.
  73. PONENTE, EHRA Europace 2011. “Rhythm control for atrial fibrillation: better results with new antiarrhythmic drugs?”. Joint Session: International Society of Cardiovascular Pharmacotherapy (ISCP)/European Heart Rhythm Association (EHRA). “Atrial repolarizing delaying agents (Vernakalant, Xention)”. Madrid, 26 de junio de 2011.
  74. PONENTE, European Heart Rhythm Association Europace 2011. Atrial remodelling: from bench to bedside. “Atrial remodelling as a target for pharmacological treatment”. Madrid, 27 de junio de 2011.
  75. CHAIRMAN, en el European Congress of the European Society of Cardiology. Long-term therapy: obstacles to be addressed. European Society of Cardiology Congress 2011. Paris, Monday 29 August.
  76. PONENTE, HDL Master Class, Praga, 29-30 de septiembre de 2011.
  77. CHAIRMAN, 3rd Meeting of the Leducq Inter-Atlantic CaMKII Alliance. Lovaina (Bélgica), 18-19 de octubre, 2011.
  78. CHAIRMAN en el IV Symposium Internacional BBVA sobre Salud Cardiovascular. “New topics in cardiovascular reseach”. Madrid, 20 de noviembre de 2011.
  79. CHAIRMAN en el Symposium “Ischemic heart disease and co-existing conditions”. 14th World Congress on cardiac Pacing and Electrophysiology/World Society of Arrhythmias. Atenas, 12 de diciembre de 2011.
  80. PONENTE, Symposium “Ischemic heart disease and co-existing conditions”. “Chronic angina, ischemia and arrhythmia- the late Na+ current as a common target?. 14th World Congress on cardiac Pacing and Electrophysiology/World Society of Arrhythmias. Atenas, 12 de diciembre de 2011.
  81. PONENTE, Symposium A new aparadigm in the treatment of ischaemic heart disease. “The late sodium curent: an innovative approach in the ischaemic heart disease treatment. Niza 10 de febrero de 2012.
  82. CHAIRMAN en el Symposium “New inflammatory biomarkers in cardiovascular prevention”. X foro Iberoamericano de Cardiología. Cádiz, 14 de abril de 2012.
  83. PONENTE en el Symposium “Therapies for atrial fibrillation – Advances and controversies in atrial fibrillation”. Antiarrhythmic/anticoagulant drug interactions: What do we know?. 18th Worl Congress on Cardiology Electrophysiology and Cardiac techniques. Niza (Francia), 13-16 de julio, 2012.
  84. CHAIRMAN del Symposium “Novel targets in the control of vascular function”. 6th European Congress of Pharmacology. EPHAR 2012, 17-20 julio 2012.
  85. CHAIRMAN del Symposium “Protective agents against myocardial ischemia/reperfusion injury”. 6th European Congress of Pharmacology. EPHAR 2012, 17-20 julio 2012.
  86. PONENTE en el Symposium “Protective agents against myocardial ischemia/reperfusion injury”: “The late sodium current as a new therapeutic target in myocardial ischemia and arrhythmias”. 6th European Congress of Pharmacology. EPHAR 2012, 17-20 julio 2012.
  87. PONENTE en el Symposium “The steps of stable ischemic heart disease patient´s management”: “The 2nd step: to reach the hub of the stable ischemic jeart disease”. European Society of Cardiology Meeting, Munich 2012, 29 agosto 2012.
  88. CHAIRMAN de la Sesión “New approaches to antiarrhythmic therapy”. European Society of Cardiology Meeting, Munich 2012, 27 agosto 2012.
  89. PONENTE, X International Meeting. Atrial fibrillation and heart failure: the ugly and the nasty. Session: Antyarrhythmic Drugs. “An appraisal for new drugs”. Bolonia, 21-23 de febrero de 2013.
  90. PONENTE, 9th Annual Congress of the European Cardiac arrhythmia Society (ECAS). Incoming treatments and techniques in atrial fibrillation. “Incoming antiarrhythmic drugs for maintaining sinus rhythm in AF patients”. Paris, 14 de abril 2013.
  91. PONENTE, Session (SP) #SP27, titled Gordon K. Moe, MD, PhD - His Laboratory and His Enormous Impact on Cardiac Electrophysiology held on. Neeting of the Heart Rhythm Society 2013, Denver (Colorado, USA),8-11 de mayo, 2013.
  92. PONENTE, FEAM (Federation of European Academies of Medicine) Spring Conference. “Clinical research with a focus on cardiovascular diseases”. RoyalCollege of Surgeons of Ireland, 28-29 de mayo de 2013.
  93. PONENTE en el Symposium "What is new in the management of risk factors in patients at increased cardiovascular risk", "Diabetes - is there any reason to prefer the newer drugs?". Annual Meeting of the ESC Working Group on Cardiovascular Pharmacology and Drug Therapy.  Roma, 7 de Junio de 2013.
  94. PRESIENTE del “Moderated Poster presentation”. Annual Meeting of the ESC Working Group on Cardiovascular Pharmacology and Drug Therapy.  Roma, 7 de Junio de 2013.
  95. PONENTE, 18th Annual Scientific Meeting of the International Society of Cardiovascular Pharmacotheraphy. Session 1: How to…? “…..Use NSAIDS  safely in CAD patients?”. Roma, 28-30 de junio de 2013.
  96. CHAIRMAN de la Sesión “Heart failure: New mechanisms – New Therapies”. ESC Congress 2013, Amsterdam, 31 de agosto – 4 de septiembre de 2013.
  97. DISCUSSANT. Póster Session. “Stem cells dans development”. ESC Congress 2013, Amsterdam, 31 de agosto – 4 de septiembre de 2013.
  98. PONENTE,  Sesión de Debate “Making sense of clinical trials”. Subgroup análisis. Should they be discouraged: “Contra”.  ESC Congress 2013, Amsterdam, 31 de agosto – 4 de septiembre de 2013.
  99. PONENTE,  Sesión de Debate “Making sense of clinical trials”. Subgroup análisis. Should they be discouraged: “ Rebuttal”.  ESC Congress 2013, Amsterdam, 31 de agosto – 4 de septiembre de 2013.